Importance Use of prognostic gene expression profile (GEP) testing in cutaneous melanoma
(CM) is rising despite a lack of endorsement as standard of care. Objective To develop …

Background Prognostic assessment of cutaneous melanoma relies on historical,
clinicopathological, and phenotypic risk factors according to American Joint Committee on …

Importance The performance of prognostic gene expression profile (GEP) tests for
cutaneous melanoma is poorly characterized. Objective To systematically assess the …

Prognostic gene expression profiling (GEP) tests for cutaneous melanoma (CM) are not
recommended in current guidelines outside of a clinical trial. However, their use is becoming …

Background A 31-gene expression profile (GEP) test that provides risk classification of
cutaneous melanoma (CM) patients has been validated in several retrospective studies. The …

The surgeon's role in the follow-up of pathologic stage I and II melanoma patients has
traditionally been minimal. Melanoma genetic expression profile (GEP) testing provides …

Background The heterogeneous behavior of patients with melanoma makes prognostication
challenging. To address this, a gene expression profile (GEP) test to predict metastatic risk …

BACKGROUND Cutaneous melanomas (CMs) with similar clinical and histopathologic
features can harbor differing capacities for metastasis. A validated gene expression profile …

Background Gene expression profiling (GEP) has been integrated into cancer treatment
decision‐making in multiple neoplasms. We prospectively evaluated the prognostic utility of …

Objective: A 31-gene expression profile (GEP) test that has been clinically validated
identifies melanoma patients with low (Class 1) or high (Class 2) risk of metastasis based on …